Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2010 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc Signs Collaboration and Option Agreement and Warrant Agreement With Novo Nordisk

DUBLIN, Ireland, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the signing of a Collaboration and Option agreement with...
December 06, 2010 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc Signs Feasibility and Option Agreement for 3 Drugs With International 'Top Ten' Pharmaceutical Company

DUBLIN, Ireland, Dec. 6, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and...
November 23, 2010 09:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc Announces Commencement of Feasibility and Option Agreement With Rebel Pharmaceuticals

DUBLIN, Ireland, Nov. 23, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery feasibility and...
November 16, 2010 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Finalises Its Phase III Development Program for Orazol(TM) in the USA

DUBLIN, Ireland, Nov. 16, 2010 (GLOBE NEWSWIRE) -- After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III...
May 07, 2010 03:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers

DUBLIN, Ireland, May 7, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals plc (IEX:MERR), a pharmaceutical development company, today announces that it has been granted a further U.S. Patent,...
March 02, 2010 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals is Issued a Key United States Patent

DUBLIN, Ireland, March 2, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals plc (IEX:MERR), an international specialty pharmaceutical company, today announced the issuance of United States Patent No....
December 07, 2009 06:30 ET | Source: Merrion Pharmaceuticals plc

Novo Nordisk Starts Phase 1 Trial With Oral Insulin Analogue -- Merrion Pharmaceuticals Earns USD 2 Million Milestone Payment

DUBLIN, Ireland, Dec. 7, 2009 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a...
May 20, 2009 09:19 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc annonce les résultats préliminaires de l'étude de phase II portant sur Orazol(tm)

DUBLIN, Irlande, 15 mai 2009 (GLOBE NEWSWIRE) - Le docteur John Fox, de la société Merrion Pharmaceuticals (« Merrion » ou la « Société » ), donnera une allocution lors de la 7ème conférence...
May 20, 2009 09:19 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc annuncia i risultati preliminari sullo studio in Fase II per Orazol(tm)

DUBLINO, Irlanda, 15 maggio 2009 (GLOBE NEWSWIRE) - Il dott. John Fox, di Merrion Pharmaceuticals ("Merrion" o la "Societa"), oggi parteciperà alla 7th International Cancer Conference a Dublino ed...
May 20, 2009 09:19 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Plc anuncia resultados preliminares en el estudio en fase II de Orazol(tm)

DUBLIN, Irlanda, 15 de mayo, 2009 (GLOBE NEWSWIRE) -- El doctor John Fox, de Merrion Pharmaceuticals ("Merrion" o la "Compañía"), dirigirá hoy la séptima Conferencia Internacional del Cáncer en...